Kombo knife combined with sorafenib in liver cancer treatment: Efficacy and safety under immune function influence

doi:10.4251/wjgo.v16.i7.3118

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (617)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-9) series, Tables (1-3) series.

Item

Count

PDF

105

HTML

333

Figures (1-9)

Tables (1-3)

Sum=548

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=51

Jul 15, 2024 (publication date) through Aug 14, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Oncol. Jul 15, 2024; 16(7): 3118-3157
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.3118

Full Size Figure Download Figure

Figure 5 Evaluation of the efficacy and safety of Kombo knife and sorafenib combination therapy. A: Overall survival in each group; B: Progression-free survival in each group; C: Adverse reactions in each group; ≤ 2 indicates adverse reactions of grade less than or equal to 2; > 3 indicates adverse reactions of grade greater than 3. HR: Hazard ratio; TACE: Transarterial chemoembolization.

Citation: Cao Y, Li PP, Qiao BL, Li QW. Kombo knife combined with sorafenib in liver cancer treatment: Efficacy and safety under immune function influence. World J Gastrointest Oncol 2024; 16(7): 3118-3157
URL: https://www.wjgnet.com/1948-5204/full/v16/i7/3118.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i7.3118